Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

JB Chem & Pharma

₹1754.8 -50.9 | 2.8%

Market Cap ₹27237 Cr.

Stock P/E 49.2

P/B 9.3

Current Price ₹1754.8

Book Value ₹ 188.3

Face Value 1

52W High ₹1935

Dividend Yield 0.7%

52W Low ₹ 1131.1

Overview Inc. Year: 1976Industry: Pharmaceuticals & Drugs

J. B. Chemicals & Pharmaceuticals Ltd is an pharmaceutical company. It is an incorporated, research-orientated organization, which is focused on imparting products both in India and International markets. The Company manufactures and markets a range of herbal remedies, pharmaceutical formulations, active pharmaceutical ingredient (APIs). The Company is engaged in manufacturing distinctiveness merchandise that comprises various pharmaceutical dosage forms like drugs, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, liquids and pills. The Company's brands include Rantac (anti-peptic ulcerant), Cilacar (calcium channel blocker), Nicardia (calcium channel blocker) and Metrogyl (amoebicides).

Read More..

JB Chem & Pharma Share Price

New

| |

Volume
Price

Quarterly Price

Show Value Show %

JB Chem & Pharma Quarterly Results

#(Fig in Cr.) Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 601 625 785 809 793 762 896 882 845 862
Other Income 5 2 1 1 3 5 6 8 7 17
Total Income 605 627 786 811 796 767 902 889 852 878
Total Expenditure 473 500 612 625 618 599 664 638 621 664
Operating Profit 133 127 174 186 178 168 238 251 230 215
Interest 1 2 6 8 8 14 12 10 12 9
Depreciation 17 22 26 28 28 32 31 32 34 41
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 114 103 142 150 141 122 194 209 184 165
Provision for Tax 30 18 37 39 35 35 52 58 50 38
Profit After Tax 84 85 105 111 106 88 142 151 134 126
Adjustments -0 -0 -0 0 0 0 0 0 0 0
Profit After Adjustments 84 85 105 111 106 88 142 151 134 126
Adjusted Earnings Per Share 5.4 5.5 6.8 7.2 6.9 5.7 9.2 9.7 8.6 8.1

JB Chem & Pharma Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 866 1022 1144 1232 1368 1414 1643 1775 2043 2424 3149 3485
Other Income 28 38 11 57 54 55 41 51 117 40 10 38
Total Income 894 1060 1155 1288 1422 1469 1685 1826 2159 2464 3159 3521
Total Expenditure 760 874 964 1026 1140 1215 1337 1397 1486 1882 2454 2587
Operating Profit 134 186 191 263 283 254 347 428 673 583 706 934
Interest 5 6 7 11 5 3 5 3 7 5 36 43
Depreciation 25 28 39 41 47 57 56 66 69 73 114 138
Exceptional Income / Expenses 0 -65 0 0 0 0 0 -10 0 0 0 0
Profit Before Tax 104 87 146 212 230 194 287 349 597 505 555 752
Provision for Tax 24 26 45 50 46 55 93 77 148 119 145 198
Profit After Tax 79 61 100 163 184 139 194 272 449 386 410 553
Adjustments 0 0 0 -0 -0 -0 -1 -0 -1 -1 -0 0
Profit After Adjustments 79 61 100 163 184 138 193 272 448 385 410 553
Adjusted Earnings Per Share 4.7 3.6 5.9 9.6 10.9 8.3 12.1 17.6 29 24.9 26.5 35.6

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 30% 21% 17% 14%
Operating Profit CAGR 21% 18% 23% 18%
PAT CAGR 6% 15% 24% 18%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 49% 32% 56% 38%
ROE Average 19% 22% 20% 15%
ROCE Average 23% 28% 26% 19%

JB Chem & Pharma Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 1020 1043 995 1184 1364 1442 1480 1435 1810 2134 2480
Minority's Interest 0 0 0 2 2 3 3 3 4 4 0
Borrowings 7 0 0 0 0 0 0 0 0 0 383
Other Non-Current Liabilities 33 31 32 31 27 46 65 63 72 475 609
Total Current Liabilities 239 276 460 797 693 736 782 516 687 455 626
Total Liabilities 1300 1351 1487 2014 2086 2226 2329 2017 2572 3069 4098
Fixed Assets 334 311 329 440 679 640 621 651 634 1277 1901
Other Non-Current Assets 22 60 258 391 200 78 120 90 45 468 598
Total Current Assets 944 981 901 1182 1207 1509 1589 1276 1894 1325 1599
Total Assets 1300 1351 1487 2014 2086 2226 2329 2017 2572 3069 4098

JB Chem & Pharma Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 220 156 12 -5 7 -21 21 32 26 22 57
Cash Flow from Operating Activities 84 -14 127 140 201 123 194 276 315 170 626
Cash Flow from Investing Activities -116 -142 -112 -28 -45 -21 -28 24 -231 2 -962
Cash Flow from Financing Activities -31 12 -1 -100 -184 -60 -156 -306 -87 -138 357
Net Cash Inflow / Outflow -63 -144 13 13 -28 43 11 -6 -3 34 20
Closing Cash & Cash Equivalent 156 12 25 9 -21 21 32 26 22 57 77

JB Chem & Pharma Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 4.69 3.63 5.92 9.58 10.85 8.28 12.06 17.6 28.98 24.93 26.48
CEPS(Rs) 6.14 5.28 8.2 12.02 13.65 11.71 15.55 21.91 33.46 29.68 33.89
DPS(Rs) 1.5 1.5 7 2.5 0.5 1 2.5 5.5 8.25 8.25 8.88
Book NAV/Share(Rs) 59.6 61.53 58.65 69.79 80.39 86.25 92.24 92.87 117.09 134.02 152.42
Core EBITDA Margin(%) 12.05 14.33 15.54 16.73 16.72 14.09 18.61 21.28 27.23 21.81 21.28
EBIT Margin(%) 12.42 9.03 13.15 18.1 17.2 13.97 17.75 19.84 29.58 20.5 18.09
Pre Tax Margin(%) 11.82 8.45 12.56 17.23 16.8 13.72 17.47 19.66 29.22 20.29 16.98
PAT Margin (%) 9.06 5.95 8.66 13.21 13.48 9.81 11.8 15.35 21.96 15.51 12.54
Cash Profit Margin (%) 11.88 8.65 12 16.55 16.93 13.84 15.19 19.09 25.32 18.44 16.04
ROA(%) 6.36 4.64 7.08 9.29 8.99 6.43 8.52 12.53 19.55 13.69 11.44
ROE(%) 8.07 5.99 9.86 14.93 14.48 9.89 13.28 18.69 27.64 19.89 18.51
ROCE(%) 10.41 8.5 13.49 17.83 16.87 13.7 19.59 23.71 36.53 25.48 22.79
Receivable days 68.16 75.3 78.41 79.28 71.84 73.15 67.63 67.22 65.62 69.29 63.16
Inventory Days 42.8 42.16 44.83 50.12 51.77 53.43 50.81 53.31 55.59 55.55 46.91
Payable days 47.94 70.5 73.91 62.53 62.76 70.44 69.69 82.55 92.33 89.07 72.35
PER(x) 7.84 17.68 16.9 13.01 15.99 18.68 14.91 14.44 21.63 31.59 37.21
Price/Book(x) 0.62 1.04 1.71 1.79 2.16 1.79 1.95 2.74 5.35 5.88 6.47
Dividend Yield(%) 4.08 2.34 7 2 0.29 0.65 1.39 2.16 1.32 1.05 0.9
EV/Net Sales(x) 0.6 1.14 1.57 1.86 2.18 1.83 1.75 2.21 4.74 5.01 4.99
EV/Core EBITDA(x) 3.87 6.29 9.42 8.74 10.54 10.15 8.28 9.17 14.4 20.84 22.28
Net Sales Growth(%) 8.01 17.98 11.97 7.64 11.1 3.32 16.23 8 15.09 18.69 29.91
EBIT Growth(%) -87.45 -14.22 63.18 46.27 5.58 -16.09 47.71 20.75 71.55 -15.58 15.93
PAT Growth(%) -88.28 -22.59 63.27 61.99 13.37 -24.77 39.83 40.43 64.66 -13.93 6.21
EPS Growth(%) -88.28 -22.61 63.12 61.87 13.24 -23.72 45.66 45.99 64.66 -13.98 6.22
Debt/Equity(x) 0.05 0.09 0.13 0.16 0.04 0.02 0.02 0.02 0.02 0.01 0.23
Current Ratio(x) 3.94 3.55 1.96 1.48 1.74 2.05 2.03 2.47 2.76 2.91 2.56
Quick Ratio(x) 3.53 3.06 1.63 1.25 1.45 1.76 1.72 1.94 2.25 2.01 1.87
Interest Cover(x) 20.61 15.74 22.33 20.94 43.81 56.54 62.74 108.09 83.43 99.6 16.4
Total Debt/Mcap(x) 0.08 0.09 0.08 0.09 0.02 0.01 0.01 0.01 0 0 0.04

JB Chem & Pharma Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 54 54 54 53.96 53.95 53.93 53.91 53.86 53.83 53.78
FII 9.12 9.22 8.85 8.66 8.8 8.63 9.54 10.05 10.35 11.05
DII 16.26 16.89 17.8 18.48 18.54 19.08 18.65 18.58 18.54 18.39
Public 20.62 19.89 19.35 18.91 18.71 18.36 17.91 17.51 17.28 16.78
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 24% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 22%
  • Debtor days have improved from 89.07 to 72.35days.
  • Company is almost debt free.

Cons

  • Stock is trading at 9.3 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

JB Chem & Pharma News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....